Catequentinib

“A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818 (Catequentinib) to Nivolumab in Solid Tumors” NCT04165330 ↗

“Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers” NCT07438886 ↗

“Anlotinib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing...” NCT03768037 ↗

“Anlotinib (AL3818) is an inhibitor targeting multiple receptor tyrosine kinases involved in tumour progression, especially VEGFR 2/3, PDGFRα/β and c-Kit.” NCT04438902 ↗

“Allotinib (AL3818) is manufactured by Zhengda Tianqing Pharmaceutical Group Co., LTD. (CTTQ; Lianyungang, Jiangsu, China) self-developed TKI drugs” NCT06429397 ↗

“BACKGROUND: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting tumour angiogenesis and proliferative signalling.” PMID 29438373 ↗ Feb 2018

“A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy” NCT02072044 ↗

“Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers” NCT07438886 ↗

“Other Name: AL3818” NCT03778853 ↗

NCT04165330 ↗

NCT05612191 ↗

NCT02558348 ↗

Show 3 more sources

“Anlotinib is a multi-target tyrosine kinase inhibitor that can target and inhibit vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR),...” NCT07142421 ↗

“Non-squamous NSCLC: almonertinib (110 mg/d) plus anlotinib (12mg/d) is started on the first day of each treatment cycle and administered every three weeks until disease...” NCT06043973 ↗

“Sintilimab 200 mg intravenously on day 1, pegaspargase 2500 IU/m² on day 1 with a maximum single dose of 3750 IU, and anlotinib 8 mg orally on days 1-14, repeated every 21 days...” NCT07678229 ↗

“Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive Non-small Cell Lung Cancer(NSCLC): An Exploratory Analysis” NCT07671560 ↗

“Thus, our study aimed to evaluate the efficacy and safety of a new regimen of anlotinib plus PD-1 inhibitor to treat refractory solid tumor.” PMID 37155342 ↗ May 2023

“Treatment comprised up to eight 21-day cycles of sintilimab 200 mg (day 1), pegaspargase 2500 IU/m2 (day 1), and anlotinib 8 mg (days 1-14)” PMID 41774854 ↗ Mar 2026

“Anlotinib: 8 mg orally once daily, starting on Day 1 of each cycle, taken for 2 consecutive weeks followed by a 1-week rest period.” NCT07239622 ↗

“Anlotinib Hydrochloride Combined With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Small Cell Lung Cancer” NCT06611657 ↗

“Antiangiogenesis targeted drugs: Bevacizumab or Anlotinib Hydrochloride, according to the standard dose treatment.” NCT06878625 ↗

“treated with irinotecan (50 mg/m2/d d1-5 Q3W) in combination with Anlotinib (12 mg Qd, 2 weeks on and 1 week off)” PMID 38310286 ↗ Feb 2024

Show 467 more sources

“Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor that has significant inhibitory activity against angiogenesis related kinases such as VEGFR1/2/3,...” NCT04684017 ↗

“Anlotinib hydrochloride, a novel oral multitarget tyrosine kinase inhibitor, has significant inhibitory activity against angiogenesis-related kinases, such as VEGFR, FGFR,...” PMID 37580661 ↗ Aug 2023

“Anlotinib hydrochloride is a novel oral tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR),...” NCT05539118 ↗

“The purpose of this study is to evaluate the efficacy and safety of Benmelstobart Injection combined with Anlotinib Hydrochloride and chemotherapy as first-line treatment for...” NCT07510594 ↗

“Anlotinib hydrochloride capsules: 10mg once a day, oral before breakfast, continuous administration for 14 days, discontinuation for 7 days, that is, 21 days (3 weeks) as a...” NCT05736952 ↗

“Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor that inhibits both tumor angiogenesis and tumor cell proliferation by blocking VEGFR, FGFR, PDGFR, and c-Kit...” NCT06062563 ↗

“Patients receive neoadjuvant therapy with oral anlotinib hydrochloride capsules and intravenous benmelstobart injection, followed by partial nephrectomy for localized renal...” NCT07627464 ↗

“Anlotinib Hydrochloride: Administered orally at a dose of 10 mg daily, taken for 2 consecutive weeks followed by 1 week off, in repeated 3-week (21-day) cycles.” NCT07849712 ↗

“Anlotinib hydrochloride capsules: Capsule; specifications 12mg; oral, once a day, every 12mg, continuous medication two weeks after 1 week deactivated.” NCT04620837 ↗

“Anlotinib Hydrochloride Capsule: Oral on an empty stomach, once a day, 1 capsule each time, orally for 2 consecutive weeks, stop for 1 week” NCT04671303 ↗

Show 52 more sources

“Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle” NCT05494060 ↗

“Anlotinib hydrochloride capsule: oral administration, once daily(QD) ;” NCT05068206 ↗

“Drug: Anlotinib Hydrochloride Capsule” NCT05549973 ↗

“Anlotinib Hydrochloride Capsules: 12mg, administered on the 1-14th day of each cycle, once a day, about half an hour before breakfast (the time of daily administration should...” NCT05800080 ↗

“Anlotinib hydrochloride capsules is a new type of small molecule multi-target tyrosine kinase inhibitor against angiogenesis.” NCT04888546 ↗

“Anlotinib Hydrochloride Capsules, 12mg/d” NCT03950518 ↗

“A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers” NCT07811297 ↗

“Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers” NCT07438886 ↗

“Hydrochloride anlotinib is a small molecular anti-angiogenesis drug with multiple targets.” NCT05772377 ↗

“Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL4303201 ↗

“Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL4303201 ↗